Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Irbesartan + ciprofibrate** is a theoretical combination of two small molecule drugs: *irbesartan*, an angiotensin II receptor blocker (ARB) used to treat hypertension and diabetic nephropathy, and *ciprofibrate*, a fibric acid derivative used to lower lipid levels in the blood, primarily for the treatment of hyperlipidemia and hypertriglyceridemia. Irbesartan lowers blood pressure by selectively antagonizing the angiotensin II type 1 receptor, thereby preventing vasoconstriction and aldosterone secretion. Ciprofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), which leads to increased oxidation of fatty acids and decreases plasma triglycerides and, to a lesser extent, cholesterol levels. There is no evidence of a fixed-dose combination or branded product combining these two agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irbesartan + ciprofibrate.